
    
      Patients with melanoma will be enrolled into two parallel cohorts; in one cohort (Intravenous
      melanoma cohort) patients will receive IV VV1 and patients in the other cohort (Intratumoral
      melanoma cohort) will receive both IV VV1 and Intratumoral VV1; both cohorts will receive IV
      cemiplimab in combination therapy with VV1 treatment. Patients with NSCLC, HCC or endometrial
      cancer will receive IV VV1 and IV cemiplimab combination therapy.
    
  